00:00It's Benzinga bringing Wall Street to Main Street.
00:02President Trump's executive order aimed at accelerating psychedelic drug development
00:07raised hopes among companies and investors that the sector could attract more capital
00:11and reduce regulatory delays, according to Reuters. Executives and investors said the
00:17order could improve coordination between the FDA and DEA and shorten some review timelines.
00:24Researchers cautioned that psychedelic treatments remain years from commercialization
00:28and still require costly clinical trials. The FDA cited slow development timelines and
00:34difficult trial designs when it rejected Lycos Therapeutics, MDMA, assisted PTSD therapy in 2024.
00:42It later granted expedited reviews to Compass Pathways, USONA Institute, and Transcend
00:48Therapeutics for psychedelic mental health treatments. Investors also said questions
00:52remain around insurance reimbursement for psychedelic therapies.
00:55For all things money, visit Benzinga.com.
Comments